Tirzepatide (Zepbound) is currently the most effective FDA-approved weight loss drug, producing roughly 20% to 25% total body weight loss in clinical trials at its highest dose. That translates to about 50 to 60 pounds for someone starting at 250 pounds. Its closest competitor, semaglutide (Wegovy), produces significant results too, but head-to-head data consistently show tirzepatide pulls ahead.
How Tirzepatide Compares to Semaglutide
Both tirzepatide and semaglutide are weekly injections approved for long-term weight management. In clinical trials, semaglutide users typically lose around 15% of their body weight over about 68 weeks. Tirzepatide users lose more. A real-world comparison published by the American College of Cardiology found that at 12 months, people on tirzepatide had lost nearly 7 percentage points more body weight than those on semaglutide. The gap widened over time: at three months the difference was about 2.4%, at six months it was 4.3%, and by one year it had grown to 6.9%.
That difference matters in practical terms. If two people both weigh 240 pounds and one takes semaglutide while the other takes tirzepatide, after a year the semaglutide user might be down around 35 pounds while the tirzepatide user could be down closer to 50 or more.
Why Tirzepatide Works Better
The key difference is in how each drug interacts with your body’s hormone receptors. Semaglutide targets a single receptor: GLP-1. This hormone naturally suppresses appetite and promotes a feeling of fullness. Tirzepatide targets two receptors: GLP-1 and a second gut hormone called GIP. Preclinical data showed that combining these two pathways produced greater fat loss, better blood sugar control, and stronger effects on lipid levels than targeting GLP-1 alone.
Think of it as two separate signals telling your brain you’re full instead of one. The combined effect isn’t just additive. Animal and human studies suggest the two hormones work synergistically, each amplifying the other’s impact on metabolism and appetite.
The Next Generation: Triple-Receptor Drugs
An investigational drug called retatrutide takes this approach one step further by targeting three receptors: GLP-1, GIP, and glucagon. In a phase 2 trial, adults with obesity who received the highest dose lost an average of 24.2% of their body weight over 48 weeks. That’s a faster and deeper weight loss than either approved drug has shown in trials of similar length.
The addition of the glucagon receptor is what sets it apart. Glucagon promotes fullness on its own, but more importantly, it ramps up energy expenditure and stimulates the body to break down stored fat for fuel. In combination with GLP-1 and GIP, which both lower blood sugar, glucagon’s tendency to raise blood sugar is counterbalanced while its fat-burning and appetite-suppressing effects remain. Retatrutide is not yet FDA-approved, but it represents where the field is heading.
All FDA-Approved Options
Six drugs are currently approved for long-term weight management in the United States:
- Tirzepatide (Zepbound): weekly injection, dual GLP-1/GIP receptor targeting, roughly 20% to 25% weight loss
- Semaglutide (Wegovy): weekly injection, GLP-1 receptor targeting, roughly 15% weight loss
- Liraglutide (Saxenda): daily injection, GLP-1 receptor targeting, roughly 5% to 8% weight loss
- Phentermine-topiramate (Qsymia): daily pill, roughly 8% to 10% weight loss
- Naltrexone-bupropion (Contrave): daily pill, roughly 5% to 6% weight loss
- Orlistat (Xenical/Alli): pill taken three times daily, roughly 3% to 5% weight loss; available in a lower dose over the counter as Alli
A seventh drug, setmelanotide (Imcivree), is approved only for people with specific rare genetic conditions confirmed by testing, so it isn’t relevant for the general population.
An Oral Option Is Catching Up
One limitation of the two most effective drugs is that both require weekly injections. A high-dose oral form of semaglutide (50 mg taken daily as a pill) showed a 15.1% weight loss at 68 weeks in a phase 3 trial. That’s comparable to injectable semaglutide’s results. In that study, 85% of participants on the oral dose lost at least 5% of their body weight, and about a third lost 20% or more. If approved at this dose for weight management, it would give people a needle-free route to similar results.
Benefits Beyond Weight Loss
GLP-1 based medications also reduce cardiovascular risk. A meta-analysis of eight large cardiovascular outcome trials found that these drugs cut the rate of major cardiovascular events (heart attack, stroke, or cardiovascular death) by about 14% in people with type 2 diabetes. That protective effect appears to go beyond what weight loss alone would explain, suggesting the drugs have direct benefits on blood vessels and inflammation.
For people who carry both excess weight and cardiovascular risk factors, this dual benefit can be a significant part of the decision to start treatment.
Side Effects and Dropout Rates
The most common side effects of both tirzepatide and semaglutide are gastrointestinal: nausea, vomiting, diarrhea, and constipation. These tend to be worst during the dose-escalation phase (the first few months, when your dose is gradually increased) and often improve with time. Both drugs start at a low dose and step up slowly specifically to minimize these effects.
Most people tolerate the medications well enough to stay on them. A Cleveland Clinic study found that among those who did stop taking injectable semaglutide or tirzepatide for obesity, only about 14.6% quit because of side effects. Cost was the more common reason for discontinuation, which points to a different kind of barrier entirely.
Cost Is the Biggest Practical Barrier
Without insurance coverage, these drugs are expensive. Wegovy runs approximately $1,300 per month at list price, and Zepbound is in a similar range. Insurance coverage varies widely. Some plans cover these medications for obesity, others cover them only for diabetes (under the brand names Ozempic and Mounjaro), and many don’t cover them at all. Manufacturer savings programs and compounding pharmacies have made access somewhat easier for some people, but affordability remains the single biggest obstacle to using the most effective options available.
The older oral medications like phentermine-topiramate and naltrexone-bupropion cost substantially less and are more commonly covered by insurance, though they produce more modest weight loss. For some people, a less potent but affordable and accessible drug is the more practical choice.